Wasamoto相关文献与解析，生知库 | 链接生命科学的每一步

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer

一线帕博利珠单抗联合铂类和培美曲塞治疗老年非鳞状非小细胞肺癌患者的疗效和安全性

Wasamoto, Satoshi; Imai, Hisao; Tsuda, Takeshi; Nagai, Yoshiaki; Kishikawa, Takayuki; Ono, Akihiro; Masubuchi, Ken; Umeda, Yukihiro; Yamada, Yutaka; Nakagawa, Junichi; Yui, Takaya; Taniguchi, Hirokazu; Kaira, Kyoichi; Kagamu, Hiroshi

肺癌

Atezolizumab-Induced Immune-Related Pneumonia on Rounded Atelectasis

阿特珠单抗诱发的免疫相关性肺炎合并圆形肺不张

期刊:Clinical Respiratory Journal

影响因子:2.3

doi:10.1111/crj.70008

Yanagisawa, Satoru; Yui, Takaya; Takechi, Hiroki; Wasamoto, Satoshi

Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer

阿特珠单抗联合卡铂和依托泊苷治疗老年广泛期小细胞肺癌患者的真实世界数据

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.4938

Shiono, Ayako; Imai, Hisao; Wasamoto, Satoshi; Tsuda, Takeshi; Nagai, Yoshiaki; Minemura, Hiroyuki; Yamada, Yutaka; Kishikawa, Takayuki; Umeda, Yukihiro; Takechi, Hiroki; Yamaguchi, Ou; Mouri, Atsuto; Kaira, Kyoichi; Taniguchi, Hirokazu; Minato, Koichi; Kagamu, Hiroshi

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

利用中性粒细胞与淋巴细胞比值预测接受帕博利珠单抗联合铂类和培美曲塞治疗的非鳞状非小细胞肺癌患者的预后

期刊:Thoracic Cancer

影响因子:2.3

doi:10.1111/1759-7714.15036

Imai, Hisao; Wasamoto, Satoshi; Tsuda, Takeshi; Nagai, Yoshiaki; Kishikawa, Takayuki; Masubuchi, Ken; Osaki, Takashi; Miura, Yosuke; Umeda, Yukihiro; Ono, Akihiro; Minemura, Hiroyuki; Yamada, Yutaka; Nakagawa, Junichi; Kozu, Yuki; Taniguchi, Hirokazu; Ohta, Hiromitsu; Kasai, Takashi; Kaira, Kyoichi; Kagamu, Hiroshi

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer

格拉斯哥预后评分可预测接受一线阿特珠单抗联合卡铂和依托泊苷治疗的小细胞肺癌患者的生存期

期刊:Frontiers in Oncology

影响因子:3.3

doi:10.3389/fonc.2022.1080729

Wasamoto, Satoshi; Imai, Hisao; Tsuda, Takeshi; Nagai, Yoshiaki; Minemura, Hiroyuki; Yamada, Yutaka; Umeda, Yukihiro; Kishikawa, Takayuki; Shiono, Ayako; Kozu, Yuki; Shiihara, Jun; Yamaguchi, Ou; Mouri, Atsuto; Kaira, Kyoichi; Kanazawa, Kenya; Taniguchi, Hirokazu; Kaburagi, Takayuki; Minato, Koichi; Kagamu, Hiroshi

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

阿特珠单抗联合卡铂和依托泊苷治疗复发性小细胞肺癌患者后，安柔比星单药治疗的疗效和安全性

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-022-01269-9

Imai, Hisao; Nagai, Yoshiaki; Minemura, Hiroyuki; Tsuda, Takeshi; Yamada, Yutaka; Wasamoto, Satoshi; Kishikawa, Takayuki; Shiono, Ayako; Shiihara, Jun; Yamaguchi, Ou; Mouri, Atsuto; Kaira, Kyoichi; Kanazawa, Kenya; Taniguchi, Hirokazu; Minato, Koichi; Kagamu, Hiroshi

Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy

化疗放疗后接受度伐利尤单抗治疗的局部晚期非小细胞肺癌患者治疗后C反应蛋白与白蛋白比值的预测价值

期刊:Thoracic Cancer

影响因子:2.3

doi:10.1111/1759-7714.14484

Araki, Taisuke; Tateishi, Kazunari; Komatsu, Masamichi; Sonehara, Kei; Wasamoto, Satoshi; Koyama, Shigeru; Yoshiike, Fumiaki; Hama, Mineyuki; Nishie, Kenichi; Kondo, Daichi; Agatsuma, Toshihiko; Kato, Akane; Takata, Munetake; Kanda, Shintaro; Hanaoka, Masayuki; Koizumi, Tomonobu

Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival

在小细胞肺癌一线化疗中，阿特珠单抗联合卡铂和依托泊苷治疗后的疾病进展后生存期对总生存期有显著影响。

期刊:Thoracic Cancer

影响因子:2.3

doi:10.1111/1759-7714.14621

Masubuchi, Ken; Imai, Hisao; Wasamoto, Satoshi; Tsuda, Takeshi; Minemura, Hiroyuki; Nagai, Yoshiaki; Yamada, Yutaka; Kishikawa, Takayuki; Umeda, Yukihiro; Shiono, Ayako; Takechi, Hiroki; Shiihara, Jun; Kaira, Kyoichi; Kanazawa, Kenya; Taniguchi, Hirokazu; Kaburagi, Takayuki; Kagamu, Hiroshi; Minato, Koichi

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

一线帕博利珠单抗单药治疗老年（≥75岁）非小细胞肺癌患者的疗效和安全性

期刊:Journal of Cancer Research and Clinical Oncology

影响因子:2.8

doi:10.1007/s00432-019-03072-1

Imai, Hisao; Wasamoto, Satoshi; Yamaguchi, Ou; Suzuki, Kensuke; Sugiyama, Tomohide; Uchino, Junji; Minemura, Hiroyuki; Osaki, Takashi; Ishii, Hisashi; Umeda, Yukihiro; Mori, Keita; Kotake, Mie; Kagamu, Hiroshi; Morozumi, Nobutoshi; Taniguchi, Hirokazu; Kasai, Takashi; Minato, Koichi; Kaira, Kyoichi

Pleomorphic Lung Carcinoma Response to Treatment With BRAF and MEK Inhibitors: A Case Report

多形性肺癌对BRAF和MEK抑制剂治疗的反应：病例报告

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer

一线帕博利珠单抗联合铂类和培美曲塞治疗老年非鳞状非小细胞肺癌患者的疗效和安全性

Atezolizumab-Induced Immune-Related Pneumonia on Rounded Atelectasis

阿特珠单抗诱发的免疫相关性肺炎合并圆形肺不张

Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer

阿特珠单抗联合卡铂和依托泊苷治疗老年广泛期小细胞肺癌患者的真实世界数据

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

利用中性粒细胞与淋巴细胞比值预测接受帕博利珠单抗联合铂类和培美曲塞治疗的非鳞状非小细胞肺癌患者的预后

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer

格拉斯哥预后评分可预测接受一线阿特珠单抗联合卡铂和依托泊苷治疗的小细胞肺癌患者的生存期

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

阿特珠单抗联合卡铂和依托泊苷治疗复发性小细胞肺癌患者后，安柔比星单药治疗的疗效和安全性

Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy

化疗放疗后接受度伐利尤单抗治疗的局部晚期非小细胞肺癌患者治疗后C反应蛋白与白蛋白比值的预测价值

Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival

在小细胞肺癌一线化疗中，阿特珠单抗联合卡铂和依托泊苷治疗后的疾病进展后生存期对总生存期有显著影响。

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

一线帕博利珠单抗单药治疗老年（≥75岁）非小细胞肺癌患者的疗效和安全性